文献速递消化道肿瘤放疗放疗物理与技术

局部晚期胰腺癌两种大分割放疗方案剂量递增潜力的比较

Comparison of the dose escalation potential for two hypofractionated radiotherapy regimens for locally advanced pancreatic cancer.
PubMed 文献 · Clin Transl Radiat Oncol · 2019-03-08

研究回顾性纳入10例未筛选的局部晚期胰腺癌患者,比较5次与15次两种大分割方案在满足危及器官约束下实现PTV 95%覆盖BED10=54 Gy及剂量递增至BED10≅100 Gy的潜力,结果显示两方案剂量递增潜力相当,但危及器官靠近PTV者通常不适合大分割剂量递增。

要点

  • 5次方案中仅1例PTV距危及器官超过1 cm者可实现基础和递增剂量下95%PTV覆盖。
  • 15次方案中除1例外所有患者均可实现基础剂量95%PTV覆盖。
  • 两种分次方案的剂量递增潜力相当,联合自适应方法可能在高BED下最大化PTV覆盖。

核心结论

  • 危及器官靠近PTV的局部晚期胰腺癌患者通常不适合大分割剂量递增。
  • 该计划研究显示可在给予90-95%PTV BED10=54 Gy的同时以BED10≅100 Gy覆盖PTV亚体积,联合自适应方法可能在高BED下最大化PTV覆盖。

研究设计与样本

  • 回顾性纳入10例未筛选的局部晚期胰腺癌患者,比较5次和15次两种大分割放疗方案的计划研究。

主要发现

  • 5次方案中,1例PTV距危及器官超过1 cm者可实现基础和递增剂量下95%PTV覆盖。
  • 5次方案中,基础和递增剂量下95%PTV覆盖分别有1例和2例患者实现,其余患者即使基础剂量覆盖也因危及器官约束而妥协。
  • 15次方案中,除1例外所有患者均可实现基础剂量95%PTV覆盖。
  • 两种分次方案均可在以BED10≅100 Gy覆盖PTV亚体积的同时改善基础剂量靶区覆盖,剂量递增潜力相当。

关键数值与推荐

  • 基础剂量:5次方案33 Gy,15次方案42.5 Gy,对应BED10=54 Gy,目标覆盖95%PTV。
  • 递增剂量:5次方案50 Gy,15次方案67.5 Gy,对应BED10≅100 Gy,PTV最大剂量限制为递增剂量的130%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine the potential for dose escalation to a biological equivalent dose BED10 ≅ 100 Gy in hypofractionated radiotherapy for locally advanced pancreatic cancer (LAPC). MATERIALS AND METHODS: Ten unselected LAPC patients were retrospectively included in the study. Two fractionation regimens were compared (5 and 15 fractions). The aim was to cover 95% of the Planning Target Volume (PTV) with a BED10 = 54 Gy (base dose = 33 Gy in 5 fractions, 42.5 Gy in 15 fractions) whilst respecting organs-at-risk (OAR) constraints. Once the highest PTV coverage was achieved dose escalation to a BED10 ≅ 100 Gy (escalated dose = 50 Gy in 5 fractions, 67.5 Gy in 15 fractions) was attempted, limiting the PTV maximum dose to 130% of the escalated dose. RESULTS: In 5 fractions, 95% PTV coverage by both base and escalated doses could be achieved for one patient with PTV more than 1 cm away from OAR. 95% and 90% PTV coverage by the base dose was achieved in one and two patients respectively. In all other patients, coverage even by the base dose had to be compromised to comply with OAR constraints. In 15 fractions, 95% PTV coverage by the base dose was feasible for all patients except one. Dose escalation allowed improvement in target coverage by the base dose in both fractionation regimen whilst covering a sub-volume of the PTV with a BED10 ≅ 100 Gy. Both fractionation schemes were equivalent in terms of dose escalation potential. CONCLUSION: LAPC patients with OAR close to the PTV are generally not eligible for hypofractionation with dose escalation. However, this planning study shows that it is possible to cover PTV sub-volumes with a BED10 ≅ 100 Gy in addition to delivering a BED10 = 54 Gy to 90-95% of the PTV as commonly prescribed to this population. Combined with an adaptive approach, this may maximize PTV coverage by a high BED on days with favourable anatomy.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Bertholet J, Hunt A, Dunlop A, et al. Comparison of the dose escalation potential for two hypofractionated radiotherapy regimens for locally advanced pancreatic cancer. Clin Transl Radiat Oncol. 2019. PMID: 30911688. doi:10.1016/j.ctro.2019.03.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。